{ "ticker": "ISRG", "cik": "0001035267", "company": "Intuitive Surgical, Inc.", "business_type": "industrial", "schema_template": "standard industrial (medical technology): product and service revenue and cost of revenue, gross profit, SG&A, R&D, a separately presented antitrust litigation settlement, income from operations, interest and other income, income taxes, net income with the noncontrolling-interest split, basic and diluted EPS and weighted shares; the full balance sheet including cash and investments; operating, investing and financing cash flow with capital expenditures and free cash flow; share repurchases; revenue by type (instruments and accessories, systems, services) and by geography (U.S. and outside the U.S.); and the company's own non-GAAP measures from its third-quarter 2026 earnings release", "reporting_currency": "USD", "converted_to_usd": false, "units": "actual US dollars (not millions); per-share amounts in dollars; share counts in actual shares", "units_notes_seen": { "FY2025 10-K consolidated balance sheets": "(IN MILLIONS, EXCEPT PAR VALUE AMOUNTS)", "FY2025 10-K consolidated statements of income": "(IN MILLIONS, EXCEPT PER SHARE AMOUNTS)", "FY2025 10-K consolidated statements of stockholders' equity": "(IN MILLIONS) (share counts in the Shares column are also in millions)", "FY2025 10-K consolidated statements of cash flows": "(IN MILLIONS)", "FY2025 10-K Note 5 revenue by geography and type": "(in millions)", "Q3 2026 10-Q condensed consolidated balance sheets": "in millions (except par values)", "Q3 2026 10-Q condensed consolidated statements of comprehensive income": "in millions (except per share amounts)", "Q3 2026 10-Q condensed consolidated statements of cash flows": "in millions", "Q3 2026 10-Q Note 5 revenue by geography and type": "(in millions)", "Q3 2026 10-Q Note 9 stockholders' equity tables": "(in millions)", "Q3 2026 10-Q Note 9 stock repurchase table": "(in millions, except per share amounts)", "Q3 2026 earnings release (Exhibit 99.1) GAAP to non-GAAP reconciliation": "(IN MILLIONS, EXCEPT PER SHARE DATA)" }, "adjustments": { "splits_applied": [], "adr_ratio": null, "fx": "none; Intuitive Surgical reports in US dollars", "split_note": "Intuitive Surgical's 3-for-1 stock split took effect in October 2021, before every period shown here, so all per-share figures and share counts are already on a post-split basis and none have been adjusted." }, "annual": [ { "fiscal_year": 2025, "label": "FY2025", "period_start": "2025-01-01", "period_end": "2025-12-31", "period_type": "fiscal year", "source_accession": "0001035267-26-000010", "income_statement": { "product_revenue": 8492600000, "service_revenue": 1572100000, "total_revenue": 10064700000, "product_cost_of_revenue": 2866100000, "service_cost_of_revenue": 556300000, "total_cost_of_revenue": 3422400000, "gross_profit": 6642300000, "selling_general_and_administrative": 2385000000, "research_and_development": 1311800000, "total_operating_expenses": 3696800000, "income_from_operations": 2945500000, "interest_and_other_income_net": 365900000, "income_before_taxes": 3311400000, "income_tax_expense": 434800000, "net_income": 2876600000, "net_income_attributable_to_noncontrolling_interest": 20600000, "net_income_attributable_to_intuitive_surgical": 2856000000, "basic_eps": 8, "diluted_eps": 7.87, "basic_shares": 356900000, "diluted_shares": 362700000 }, "balance_sheet": { "cash_and_cash_equivalents": 3368000000, "short_term_investments": 2566900000, "accounts_receivable_net": 1527300000, "inventory": 1840000000, "prepaids_and_other_current_assets": 477300000, "total_current_assets": 9779500000, "property_plant_and_equipment_net": 5342400000, "long_term_investments": 3099200000, "deferred_tax_assets": 1018600000, "intangible_and_other_assets_net": 848700000, "goodwill": 370300000, "total_assets": 20458700000, "accounts_payable": 255100000, "accrued_compensation_and_employee_benefits": 648400000, "deferred_revenue": 506700000, "other_accrued_liabilities": 596000000, "total_current_liabilities": 2006200000, "other_long_term_liabilities": 510800000, "total_liabilities": 2517000000, "additional_paid_in_capital": 10768500000, "retained_earnings": 7011800000, "accumulated_other_comprehensive_income_loss": 43300000, "total_intuitive_surgical_stockholders_equity": 17824000000, "noncontrolling_interest_in_joint_venture": 117700000, "total_stockholders_equity": 17941700000, "common_shares_outstanding": 355100000, "cash_cash_equivalents_and_investments": 9034100000 }, "cash_flow": { "depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 614700000, "amortization_of_intangible_and_other_assets": 62400000, "deferred_income_taxes": 19100000, "share_based_compensation": 788200000, "operating_cash_flow": 3030500000, "purchases_of_investments": -1215900000, "proceeds_from_sales_of_investments": 259900000, "proceeds_from_maturities_of_investments": 2175500000, "capital_expenditures": -539800000, "acquisitions_net_of_cash_intellectual_property_and_other_investing": -13900000, "net_cash_from_investing_activities": 665800000, "proceeds_from_employee_stock_plans": 350300000, "taxes_paid_for_net_share_settlement_of_equity_awards": -419100000, "repurchases_of_common_stock": -2295300000, "net_cash_from_financing_activities": -2364100000, "effect_of_exchange_rate_changes": 12800000, "net_change_in_cash_cash_equivalents_and_restricted_cash": 1345000000, "cash_cash_equivalents_and_restricted_cash_end_of_period": 3407400000, "free_cash_flow": 2490700000 }, "revenue_by_type": { "instruments_and_accessories": 6018900000, "systems": 2473700000, "services": 1572100000, "total_revenue": 10064700000 }, "revenue_by_geography": { "united_states": 6815800000, "outside_united_states": 3248900000 } }, { "fiscal_year": 2024, "label": "FY2024", "period_start": "2024-01-01", "period_end": "2024-12-31", "period_type": "fiscal year", "source_accession": "0001035267-26-000010", "income_statement": { "product_revenue": 7045000000, "service_revenue": 1307100000, "total_revenue": 8352100000, "product_cost_of_revenue": 2313100000, "service_cost_of_revenue": 404800000, "total_cost_of_revenue": 2717900000, "gross_profit": 5634200000, "selling_general_and_administrative": 2140000000, "research_and_development": 1145300000, "total_operating_expenses": 3285300000, "income_from_operations": 2348900000, "interest_and_other_income_net": 324900000, "income_before_taxes": 2673800000, "income_tax_expense": 336300000, "net_income": 2337500000, "net_income_attributable_to_noncontrolling_interest": 14900000, "net_income_attributable_to_intuitive_surgical": 2322600000, "basic_eps": 6.54, "diluted_eps": 6.42, "basic_shares": 355200000, "diluted_shares": 362000000 }, "balance_sheet": { "cash_and_cash_equivalents": 2027400000, "short_term_investments": 1985900000, "accounts_receivable_net": 1225400000, "inventory": 1487200000, "prepaids_and_other_current_assets": 385100000, "total_current_assets": 7111000000, "property_plant_and_equipment_net": 4646600000, "long_term_investments": 4819100000, "deferred_tax_assets": 1045100000, "intangible_and_other_assets_net": 773900000, "goodwill": 347500000, "total_assets": 18743200000, "accounts_payable": 193400000, "accrued_compensation_and_employee_benefits": 535600000, "deferred_revenue": 468800000, "other_accrued_liabilities": 547500000, "total_current_liabilities": 1745300000, "other_long_term_liabilities": 468300000, "total_liabilities": 2213600000, "additional_paid_in_capital": 9681300000, "retained_earnings": 6803300000, "accumulated_other_comprehensive_income_loss": -51300000, "total_intuitive_surgical_stockholders_equity": 16433700000, "noncontrolling_interest_in_joint_venture": 95900000, "total_stockholders_equity": 16529600000, "common_shares_outstanding": 356600000, "cash_cash_equivalents_and_investments": 8832400000 }, "cash_flow": { "depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 445300000, "amortization_of_intangible_and_other_assets": 54400000, "deferred_income_taxes": -135300000, "share_based_compensation": 676800000, "operating_cash_flow": 2415000000, "purchases_of_investments": -5139600000, "proceeds_from_sales_of_investments": 100200000, "proceeds_from_maturities_of_investments": 2878800000, "capital_expenditures": -1111200000, "acquisitions_net_of_cash_intellectual_property_and_other_investing": -1000000, "net_cash_from_investing_activities": -3272800000, "proceeds_from_employee_stock_plans": 429400000, "taxes_paid_for_net_share_settlement_of_equity_awards": -270000000, "repurchases_of_common_stock": 0, "net_cash_from_financing_activities": 150900000, "effect_of_exchange_rate_changes": -800000, "net_change_in_cash_cash_equivalents_and_restricted_cash": -707700000, "cash_cash_equivalents_and_restricted_cash_end_of_period": 2062400000, "free_cash_flow": 1303800000 }, "revenue_by_type": { "instruments_and_accessories": 5079000000, "systems": 1966000000, "services": 1307100000, "total_revenue": 8352100000 }, "revenue_by_geography": { "united_states": 5589400000, "outside_united_states": 2762700000 } }, { "fiscal_year": 2023, "label": "FY2023", "period_start": "2023-01-01", "period_end": "2023-12-31", "period_type": "fiscal year", "source_accession": "0001035267-26-000010", "income_statement": { "product_revenue": 5956300000, "service_revenue": 1167800000, "total_revenue": 7124100000, "product_cost_of_revenue": 2041800000, "service_cost_of_revenue": 352800000, "total_cost_of_revenue": 2394600000, "gross_profit": 4729500000, "selling_general_and_administrative": 1963900000, "research_and_development": 998800000, "total_operating_expenses": 2962700000, "income_from_operations": 1766800000, "interest_and_other_income_net": 192100000, "income_before_taxes": 1958900000, "income_tax_expense": 141600000, "net_income": 1817300000, "net_income_attributable_to_noncontrolling_interest": 19300000, "net_income_attributable_to_intuitive_surgical": 1798000000, "basic_eps": 5.12, "diluted_eps": 5.03, "basic_shares": 351200000, "diluted_shares": 357400000 }, "cash_flow": { "depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 401600000, "amortization_of_intangible_and_other_assets": 53200000, "deferred_income_taxes": -280800000, "share_based_compensation": 592800000, "operating_cash_flow": 1813800000, "purchases_of_investments": -2207400000, "proceeds_from_sales_of_investments": 230300000, "proceeds_from_maturities_of_investments": 2690100000, "capital_expenditures": -1064200000, "acquisitions_net_of_cash_intellectual_property_and_other_investing": -8900000, "net_cash_from_investing_activities": -360100000, "proceeds_from_employee_stock_plans": 296300000, "taxes_paid_for_net_share_settlement_of_equity_awards": -164700000, "repurchases_of_common_stock": -416300000, "net_cash_from_financing_activities": -287600000, "effect_of_exchange_rate_changes": 3300000, "net_change_in_cash_cash_equivalents_and_restricted_cash": 1169400000, "cash_cash_equivalents_and_restricted_cash_end_of_period": 2770100000, "free_cash_flow": 749600000 }, "revenue_by_type": { "instruments_and_accessories": 4276600000, "systems": 1679700000, "services": 1167800000, "total_revenue": 7124100000 }, "revenue_by_geography": { "united_states": 4688600000, "outside_united_states": 2435500000 } } ], "quarterly": [ { "fiscal_year": 2026, "fiscal_quarter": 3, "label": "Q3 FY2026", "period_start": "2026-07-01", "period_end": "2026-09-30", "period_type": "three months", "source_accession": "0001035267-26-000071", "income_statement": { "product_revenue": 2566500000, "service_revenue": 482200000, "total_revenue": 3048700000, "product_cost_of_revenue": 797700000, "service_cost_of_revenue": 166700000, "total_cost_of_revenue": 964400000, "gross_profit": 2084300000, "selling_general_and_administrative": 633400000, "antitrust_class_action_litigation_settlement": 450000000, "research_and_development": 408300000, "total_operating_expenses": 1491700000, "income_from_operations": 592600000, "interest_and_other_income_net": 75800000, "income_before_taxes": 668400000, "income_tax_expense": 144000000, "net_income": 524400000, "net_income_attributable_to_noncontrolling_interest": 1600000, "net_income_attributable_to_intuitive_surgical": 522800000, "basic_eps": 1.5, "diluted_eps": 1.49, "basic_shares": 349000000, "diluted_shares": 351600000 }, "balance_sheet": { "cash_and_cash_equivalents": 2978100000, "short_term_investments": 1064400000, "accounts_receivable_net": 1721300000, "inventory": 2128200000, "prepaids_and_other_current_assets": 536300000, "total_current_assets": 8428300000, "property_plant_and_equipment_net": 5676200000, "long_term_investments": 2757900000, "deferred_tax_assets": 719700000, "intangible_and_other_assets_net": 1209200000, "goodwill": 557800000, "total_assets": 19349100000, "accounts_payable": 279500000, "accrued_compensation_and_employee_benefits": 505900000, "deferred_revenue": 541200000, "other_accrued_liabilities": 1206400000, "total_current_liabilities": 2533000000, "other_long_term_liabilities": 698300000, "total_liabilities": 3231300000, "additional_paid_in_capital": 11521100000, "retained_earnings": 4525100000, "accumulated_other_comprehensive_income_loss": -60300000, "total_intuitive_surgical_stockholders_equity": 15986200000, "noncontrolling_interest_in_joint_venture": 131600000, "total_stockholders_equity": 16117800000, "common_shares_outstanding": 346600000, "cash_cash_equivalents_and_investments": 6800400000 }, "revenue_by_type": { "instruments_and_accessories": 1797400000, "systems": 769100000, "services": 482200000, "total_revenue": 3048700000 }, "revenue_by_geography": { "united_states": 2063000000, "outside_united_states": 985700000 }, "shareholder_returns": { "shares_repurchased": 7800000, "average_price_per_share_repurchased": 377.01, "aggregate_cost_of_shares_repurchased": 2939800000 }, "non_gaap": { "non_gaap_gross_profit": 2129600000, "non_gaap_income_from_operations": 1269700000, "non_gaap_net_income_attributable_to_intuitive_surgical": 1054500000, "non_gaap_diluted_eps": 3 }, "non_gaap_source_accession": "0001035267-26-000067" }, { "fiscal_year": 2025, "fiscal_quarter": 3, "label": "Q3 FY2025", "period_start": "2025-07-01", "period_end": "2025-09-30", "period_type": "three months", "source_accession": "0001035267-26-000071", "income_statement": { "product_revenue": 2109200000, "service_revenue": 395900000, "total_revenue": 2505100000, "product_cost_of_revenue": 699400000, "service_cost_of_revenue": 143300000, "total_cost_of_revenue": 842700000, "gross_profit": 1662400000, "selling_general_and_administrative": 573300000, "antitrust_class_action_litigation_settlement": 0, "research_and_development": 329400000, "total_operating_expenses": 902700000, "income_from_operations": 759700000, "interest_and_other_income_net": 95500000, "income_before_taxes": 855200000, "income_tax_expense": 146000000, "net_income": 709200000, "net_income_attributable_to_noncontrolling_interest": 4800000, "net_income_attributable_to_intuitive_surgical": 704400000, "basic_eps": 1.98, "diluted_eps": 1.95, "basic_shares": 356600000, "diluted_shares": 361800000 }, "revenue_by_type": { "instruments_and_accessories": 1518800000, "systems": 590400000, "services": 395900000, "total_revenue": 2505100000 }, "revenue_by_geography": { "united_states": 1717600000, "outside_united_states": 787500000 }, "shareholder_returns": { "shares_repurchased": 4000000, "average_price_per_share_repurchased": 479.6, "aggregate_cost_of_shares_repurchased": 1919600000 }, "non_gaap": { "non_gaap_gross_profit": 1703800000, "non_gaap_income_from_operations": 975900000, "non_gaap_net_income_attributable_to_intuitive_surgical": 867200000, "non_gaap_diluted_eps": 2.4 }, "balance_sheet": { "total_intuitive_surgical_stockholders_equity": 16929700000, "noncontrolling_interest_in_joint_venture": 112400000, "total_stockholders_equity": 17042100000, "common_shares_outstanding": 354900000, "additional_paid_in_capital": 10478800000, "retained_earnings": 6424000000, "accumulated_other_comprehensive_income_loss": 26500000 }, "non_gaap_source_accession": "0001035267-26-000067", "balance_sheet_source": "The Q3 2026 10-Q prints no September 30, 2025 balance sheet; the equity figures and shares outstanding shown for Q3 FY2025 are the September 30, 2025 ending balances in that 10-Q's stockholders' equity note (Note 9)." } ], "year_to_date": { "fiscal_year": 2026, "label": "Nine months ended September 30, 2026", "period_start": "2026-01-01", "period_end": "2026-09-30", "period_type": "nine months", "source_accession": "0001035267-26-000071", "prior_year_comparative": { "fiscal_year": 2025, "label": "Nine months ended September 30, 2025", "period_start": "2025-01-01", "period_end": "2025-09-30", "period_type": "nine months", "source_accession": "0001035267-26-000071", "income_statement": { "product_revenue": 6048400000, "service_revenue": 1150100000, "total_revenue": 7198500000, "product_cost_of_revenue": 2056300000, "service_cost_of_revenue": 404200000, "total_cost_of_revenue": 2460500000, "gross_profit": 4738000000, "selling_general_and_administrative": 1697900000, "antitrust_class_action_litigation_settlement": 0, "research_and_development": 958900000, "total_operating_expenses": 2656800000, "income_from_operations": 2081200000, "interest_and_other_income_net": 274600000, "income_before_taxes": 2355800000, "income_tax_expense": 278700000, "net_income": 2077100000, "net_income_attributable_to_noncontrolling_interest": 15900000, "net_income_attributable_to_intuitive_surgical": 2061200000, "basic_eps": 5.77, "diluted_eps": 5.67, "basic_shares": 357500000, "diluted_shares": 363500000 }, "cash_flow": { "depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 446300000, "amortization_of_intangible_and_other_assets": 37300000, "deferred_income_taxes": 58600000, "share_based_compensation": 584900000, "operating_cash_flow": 2138000000, "purchases_of_investments": -790900000, "proceeds_from_sales_of_investments": 249100000, "proceeds_from_maturities_of_investments": 1795500000, "proceeds_from_sale_of_assets": 0, "capital_expenditures": -377300000, "acquisitions_net_of_cash_intellectual_property_and_other_investing": -1200000, "net_cash_from_investing_activities": 875200000, "proceeds_from_employee_stock_plans": 273700000, "taxes_paid_for_net_share_settlement_of_equity_awards": -406000000, "repurchases_of_common_stock": -2094300000, "other_financing_activities": 0, "net_cash_from_financing_activities": -2226600000, "effect_of_exchange_rate_changes": 500000, "net_change_in_cash_cash_equivalents_and_restricted_cash": 787100000, "cash_cash_equivalents_and_restricted_cash_end_of_period": 2849500000, "free_cash_flow": 1760700000 }, "revenue_by_type": { "instruments_and_accessories": 4360600000, "systems": 1687800000, "services": 1150100000, "total_revenue": 7198500000 }, "revenue_by_geography": { "united_states": 4885200000, "outside_united_states": 2313300000 }, "shareholder_returns": { "shares_repurchased": 4400000, "average_price_per_share_repurchased": 482.66, "aggregate_cost_of_shares_repurchased": 2100600000 }, "non_gaap": { "non_gaap_gross_profit": 4857500000, "non_gaap_income_from_operations": 2690000000, "non_gaap_net_income_attributable_to_intuitive_surgical": 2326600000, "non_gaap_diluted_eps": 6.4 }, "non_gaap_source_accession": "0001035267-26-000067" }, "income_statement": { "product_revenue": 7323500000, "service_revenue": 1388300000, "total_revenue": 8711800000, "product_cost_of_revenue": 2354700000, "service_cost_of_revenue": 481900000, "total_cost_of_revenue": 2836600000, "gross_profit": 5875200000, "selling_general_and_administrative": 1864600000, "antitrust_class_action_litigation_settlement": 450000000, "research_and_development": 1140800000, "total_operating_expenses": 3455400000, "income_from_operations": 2419800000, "interest_and_other_income_net": 243600000, "income_before_taxes": 2663400000, "income_tax_expense": 489800000, "net_income": 2173600000, "net_income_attributable_to_noncontrolling_interest": 11200000, "net_income_attributable_to_intuitive_surgical": 2162400000, "basic_eps": 6.13, "diluted_eps": 6.07, "basic_shares": 352600000, "diluted_shares": 356200000 }, "cash_flow": { "depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 559000000, "amortization_of_intangible_and_other_assets": 85000000, "deferred_income_taxes": 315900000, "share_based_compensation": 632000000, "operating_cash_flow": 3197000000, "purchases_of_investments": -1460300000, "proceeds_from_sales_of_investments": 1845100000, "proceeds_from_maturities_of_investments": 1373500000, "proceeds_from_sale_of_assets": 46000000, "capital_expenditures": -329000000, "acquisitions_net_of_cash_intellectual_property_and_other_investing": -518600000, "net_cash_from_investing_activities": 956700000, "proceeds_from_employee_stock_plans": 283800000, "taxes_paid_for_net_share_settlement_of_equity_awards": -378500000, "repurchases_of_common_stock": -4419200000, "other_financing_activities": -21300000, "net_cash_from_financing_activities": -4535200000, "effect_of_exchange_rate_changes": -3500000, "net_change_in_cash_cash_equivalents_and_restricted_cash": -385000000, "cash_cash_equivalents_and_restricted_cash_end_of_period": 3022400000, "free_cash_flow": 2868000000 }, "revenue_by_type": { "instruments_and_accessories": 5218700000, "systems": 2104800000, "services": 1388300000, "total_revenue": 8711800000 }, "revenue_by_geography": { "united_states": 5779500000, "outside_united_states": 2932300000 }, "shareholder_returns": { "shares_repurchased": 11000000, "average_price_per_share_repurchased": 405.51, "aggregate_cost_of_shares_repurchased": 4446300000 }, "non_gaap": { "non_gaap_gross_profit": 6032600000, "non_gaap_income_from_operations": 3564500000, "non_gaap_net_income_attributable_to_intuitive_surgical": 2957700000, "non_gaap_diluted_eps": 8.3 }, "non_gaap_source_accession": "0001035267-26-000067" }, "trailing_twelve_months": { "label": "Twelve months ended September 30, 2026", "period_start": "2025-10-01", "period_end": "2026-09-30", "period_type": "trailing twelve months", "source_accession": "0001035267-26-000071", "derived_from_accessions": [ "0001035267-26-000010", "0001035267-26-000071" ], "income_statement": { "product_revenue": 9767700000, "service_revenue": 1810300000, "total_revenue": 11578000000, "product_cost_of_revenue": 3164500000, "service_cost_of_revenue": 634000000, "total_cost_of_revenue": 3798500000, "gross_profit": 7779500000, "selling_general_and_administrative": 2551700000, "research_and_development": 1493700000, "total_operating_expenses": 4495400000, "income_from_operations": 3284100000, "interest_and_other_income_net": 334900000, "income_before_taxes": 3619000000, "income_tax_expense": 645900000, "net_income": 2973100000, "net_income_attributable_to_noncontrolling_interest": 15900000, "net_income_attributable_to_intuitive_surgical": 2957200000, "antitrust_class_action_litigation_settlement": 450000000 }, "cash_flow": { "operating_cash_flow": 4089500000, "capital_expenditures": -491500000, "share_based_compensation": 835300000, "repurchases_of_common_stock": -4620200000, "free_cash_flow": 3598000000 }, "revenue_by_type": { "instruments_and_accessories": 6877000000, "systems": 2890700000, "services": 1810300000, "total_revenue": 11578000000 } }, "notes": [ "Annual figures for FY2023, FY2024 and FY2025 are from the FY2025 Form 10-K (accession 0001035267-26-000010), which prints three years of income and cash flow statements and two year-end balance sheets (December 31, 2025 and 2024); FY2023 therefore carries no balance sheet.", "Quarterly figures for the three months ended September 30, 2026 and 2025, the nine-month year-to-date figures and the September 30, 2026 balance sheet are from the Q3 2026 Form 10-Q (accession 0001035267-26-000071). The December 31, 2025 balance sheet column the 10-Q reprints matches the 10-K line for line.", "Q3 2026 results include a $450.0 million pre-tax charge for the settlement of the antitrust class action litigation (\"In re: da Vinci Surgical Robot Antitrust Litigation\"), which the 10-Q presents as a separate operating-expense line. The earnings release instead includes it within selling, general and administrative expense, which it reports as $1,083.4 million for the quarter ($633.4 million plus the $450.0 million settlement). The release states the charge was $347 million net of tax, or $0.99 per diluted share, and that the settlement remains subject to court approval. This charge is why Q3 2026 income from operations ($592.6 million) fell from Q3 2025 ($759.7 million) while revenue rose 22%.", "The 10-Q prints cash flows for the nine months only, so the quarterly entries carry no cash flow figures; nine-month cash flows are in the year-to-date block.", "The balance sheets present no debt or borrowings line, so no total-debt figure is shown. The company paid no dividends; the only dividend line on the cash flow statement is the joint venture's $8.0 million payment to its noncontrolling holder in FY2024.", "Cash flow outflows are stored as negative numbers, as the statements print them in parentheses.", "The trailing-twelve-month block is computed as FY2025 plus the nine months ended September 30, 2026 less the nine months ended September 30, 2025; per-share figures and share counts are not computed for it. Its SG&A excludes the $450.0 million settlement, which is shown on its own line.", "Non-GAAP figures for Q3 2026, Q3 2025 and both nine-month periods are the company's own, from the GAAP to non-GAAP reconciliation in its Q3 2026 earnings release (accession 0001035267-26-000067); they are not GAAP measures." ], "uncertainties": [ "Three-month cash flow figures for Q3 2026 and Q3 2025 (operating cash flow, capital expenditures, free cash flow) are not available: the Q3 2026 10-Q prints only nine-month cash flows, and the six-month figures needed to difference them are in the Q2 2026 10-Q, which is not among the filings read for this page.", "The FY2025 10-K has no separate litigation-settlement line, so FY2025 SG&A includes whatever litigation charges arose that year; the earnings release attributes $454.9 million of Q3 2026 litigation charges to SG&A, of which $450.0 million is the antitrust settlement shown separately in the 10-Q." ], "definitions": { "net_income": "Consolidated net income, including the share earned by the noncontrolling interest in the company's joint venture with Fosun Pharma. Earnings per share are struck on net_income_attributable_to_intuitive_surgical.", "antitrust_class_action_litigation_settlement": "The $450.0 million charge for the settlement of the antitrust class action litigation, which the Q3 2026 10-Q presents as its own operating-expense line. Zero where the 10-Q prints a dash; not presented in the FY2025 10-K.", "free_cash_flow": "Net cash provided by operating activities less purchases of property, plant, and equipment. Computed here from the cash flow statement; it is not a figure the company reports.", "capital_expenditures": "Purchases of property, plant, and equipment as printed on the cash flow statement (shown as a negative outflow).", "cash_cash_equivalents_and_investments": "Cash and cash equivalents plus short-term and long-term investments, summed from the balance sheet. The company's Q3 2026 earnings release prints the same total: $6,800.4 million at September 30, 2026 and $9,034.1 million at December 31, 2025.", "common_shares_outstanding": "Common shares issued and outstanding at the period end, from the stockholders' equity statement.", "revenue_by_type": "Revenue disaggregated by type in the revenue note: instruments and accessories plus systems make up product revenue; services equals service revenue.", "non_gaap": "The company's own non-GAAP measures from its Q3 2026 earnings release (Exhibit 99.1 to the Form 8-K, accession 0001035267-26-000067). They exclude share-based compensation and long-term incentive plan expense, amortization of intangible assets, litigation charges (including the $450 million antitrust settlement), acquisition-related items, gains on sale of businesses and assets, gains or losses on strategic investments and tax adjustments, as the release defines them.", "trailing_twelve_months": "FY2025 from the FY2025 10-K plus the nine months ended September 30, 2026, less the nine months ended September 30, 2025, both from the Q3 2026 10-Q." }, "headline": { "period": "Q3 FY2026", "period_end_words": "September 30, 2026", "metrics": [ { "label": "Revenue", "format": "usd", "value": 3048700000, "text": "$3.05 billion", "exact": "$3,048,700,000", "compact": "$3.05B", "abs": "$3.05 billion", "prior_value": 2505100000, "prior": "$2.51 billion", "priorabs": "$2.51 billion", "yoy": "up 21.7%", "source": { "array": "quarterly", "field": "income_statement.total_revenue", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001035267-26-000071", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001035267-26-000071", "gap_days": 365 } }, { "label": "Net income", "format": "usd", "value": 522800000, "text": "$522.8 million", "exact": "$522,800,000", "compact": "$522.80M", "abs": "$522.8 million", "prior_value": 704400000, "prior": "$704.4 million", "priorabs": "$704.4 million", "yoy": "down 25.8%", "source": { "array": "quarterly", "field": "income_statement.net_income_attributable_to_intuitive_surgical", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001035267-26-000071", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001035267-26-000071", "gap_days": 365 } }, { "label": "Diluted EPS", "format": "eps", "value": 1.49, "text": "$1.49", "exact": "$1.49", "compact": "$1.49", "abs": "$1.49", "prior_value": 1.95, "prior": "$1.95", "priorabs": "$1.95", "yoy": "down 23.6%", "source": { "array": "quarterly", "field": "income_statement.diluted_eps", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001035267-26-000071", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001035267-26-000071", "gap_days": 365 } }, { "label": "Antitrust settlement charge", "format": "usd", "value": 450000000, "text": "$450 million", "exact": "$450,000,000", "compact": "$450.00M", "abs": "$450 million", "prior_value": null, "prior": null, "priorabs": null, "yoy": null, "source": { "array": "quarterly", "field": "income_statement.antitrust_class_action_litigation_settlement", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001035267-26-000071" } }, { "label": "Non-GAAP diluted EPS", "format": "eps", "value": 3, "text": "$3.00", "exact": "$3.00", "compact": "$3.00", "abs": "$3.00", "prior_value": 2.4, "prior": "$2.40", "priorabs": "$2.40", "yoy": "up 25.0%", "source": { "array": "quarterly", "field": "non_gaap.non_gaap_diluted_eps", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001035267-26-000067", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001035267-26-000067", "gap_days": 365 } } ], "summary": "Intuitive Surgical reported revenue of $3.05 billion for Q3 FY2026, the quarter ended September 30, 2026, up 21.7% from a year earlier, with instruments and accessories, systems and services all growing. Net income attributable to Intuitive was $522.8 million, or $1.49 per diluted share, down 25.8% from $704.4 million, because the quarter carried a $450 million charge for its agreement to settle a hospital antitrust class action, which still needs court approval. On the company's own non-GAAP basis, which excludes the charge, diluted earnings per share were $3.00, up 25.0% from $2.40.", "qa": [ { "q": "How much revenue did Intuitive Surgical report in Q3 FY2026?", "a": "Intuitive Surgical reported revenue of $3.05 billion for Q3 FY2026, the quarter ended September 30, 2026. That is up 21.7% from $2.51 billion in the same quarter a year earlier." }, { "q": "Why did Intuitive Surgical's earnings fall in Q3 FY2026?", "a": "Intuitive Surgical's net income attributable to the company fell to $522.8 million in Q3 FY2026, down 25.8% from $704.4 million a year earlier, and diluted earnings per share fell to $1.49 from $1.95. The decline reflects a $450 million operating-expense charge, recorded in the quarter, for settling a hospital antitrust class action, while revenue was up 21.7% from a year earlier." }, { "q": "What is Intuitive Surgical's antitrust class action settlement?", "a": "Intuitive Surgical agreed after the quarter to make a one-time payment of $450 million to settle the hospital class action known as In re: da Vinci Surgical Robot Antitrust Litigation, with agreed injunctive relief and no admission of liability. The company recorded the full amount as an operating-expense charge and a liability for the quarter ended September 30, 2026, and the settlement still needs preliminary and final court approval." }, { "q": "What was Intuitive Surgical's non-GAAP EPS in Q3 FY2026?", "a": "Intuitive Surgical reported non-GAAP diluted earnings per share of $3.00 for Q3 FY2026, up 25.0% from $2.40 a year earlier, compared with GAAP diluted earnings per share of $1.49. The company's non-GAAP measure excludes items including the antitrust settlement charge, share-based compensation and amortization of intangible assets." } ] }, "company_details": { "Name": "Intuitive Surgical Inc", "Ticker": "ISRG", "CIK": "0001035267", "Exchange": "Nasdaq", "State": "California", "Incorporation": "Delaware", "SIC": "3842", "Office": "Industrial Applications and Services", "Industry": "Orthopedic, Prosthetic & Surgical Appliances & Supplies" }, "next_filing": { "predicted_date": "2027-02-02", "predicted_type": "10-K" }, "fiscal_period": { "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "form": "10-Q", "accession": "0001035267-26-000071", "fiscal_year_end": "1231", "source": "facts" }, "source_filings": [ { "role": "annual", "current": false, "form": "10-K", "fiscal_year": 2025, "fiscal_period": "FY", "tag": "FY25", "period_end": "2025-12-31", "filed": "2026-02-03", "accession": "0001035267-26-000010", "url": "https://www.sec.gov/Archives/edgar/data/1035267/000103526726000010/isrg-20251231.htm", "source": "reported" }, { "role": "quarterly", "current": true, "form": "10-Q", "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "filed": "2026-10-21", "accession": "0001035267-26-000071", "url": "https://www.sec.gov/Archives/edgar/data/1035267/000103526726000071/isrg-20260930.htm", "source": "facts" } ], "figure_sources": { "about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '#', and the link is documents[] + '#': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.", "documents": { "d1": "https://www.sec.gov/Archives/edgar/data/1035267/000103526726000010/isrg-20251231.htm", "d2": "https://www.sec.gov/Archives/edgar/data/1035267/000103526726000071/isrg-20260930.htm" }, "annual": [ { "period_end": "2025-12-31", "income_statement": { "product_revenue": "d1#f-133", "service_revenue": "d1#f-136", "total_revenue": "d1#f-139", "product_cost_of_revenue": "d1#f-142", "service_cost_of_revenue": "d1#f-145", "total_cost_of_revenue": "d1#f-148", "gross_profit": "d1#f-151", "selling_general_and_administrative": "d1#f-154", "research_and_development": "d1#f-157", "total_operating_expenses": "d1#f-160", "income_from_operations": "d1#f-163", "interest_and_other_income_net": "d1#f-166", "income_before_taxes": "d1#f-169", "income_tax_expense": "d1#f-172", "net_income": "d1#f-175", "net_income_attributable_to_noncontrolling_interest": "d1#f-344", "net_income_attributable_to_intuitive_surgical": "d1#f-181", "basic_eps": "d1#f-184", "diluted_eps": "d1#f-187", "basic_shares": "d1#f-190", "diluted_shares": "d1#f-193" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-56", "short_term_investments": "d1#f-58", "accounts_receivable_net": "d1#f-62", "inventory": "d1#f-64", "prepaids_and_other_current_assets": "d1#f-67", "total_current_assets": "d1#f-69", "property_plant_and_equipment_net": "d1#f-71", "deferred_tax_assets": "d1#f-75", "intangible_and_other_assets_net": "d1#f-77", "goodwill": "d1#f-79", "total_assets": "d1#f-81", "accounts_payable": "d1#f-83", "accrued_compensation_and_employee_benefits": "d1#f-85", "deferred_revenue": "d1#f-87", "other_accrued_liabilities": "d1#f-89", "total_current_liabilities": "d1#f-91", "other_long_term_liabilities": "d1#f-93", "total_liabilities": "d1#f-95", "additional_paid_in_capital": "d1#f-119", "retained_earnings": "d1#f-121", "accumulated_other_comprehensive_income_loss": "d1#f-123", "total_intuitive_surgical_stockholders_equity": "d1#f-125", "noncontrolling_interest_in_joint_venture": "d1#f-127", "total_stockholders_equity": "d1#f-129", "common_shares_outstanding": "d1#f-113", "cash_cash_equivalents_and_investments": "d1#f-611" }, "cash_flow": { "depreciation_and_loss_on_disposal_of_property_plant_and_equipment": "d1#f-356", "amortization_of_intangible_and_other_assets": "d1#f-359", "deferred_income_taxes": "d1#f-368", "share_based_compensation": "d1#f-371", "operating_cash_flow": "d1#f-395", "purchases_of_investments": "d1#f-398", "proceeds_from_sales_of_investments": "d1#f-401", "proceeds_from_maturities_of_investments": "d1#f-404", "capital_expenditures": "d1#f-407", "acquisitions_net_of_cash_intellectual_property_and_other_investing": "d1#f-410", "net_cash_from_investing_activities": "d1#f-413", "proceeds_from_employee_stock_plans": "d1#f-416", "taxes_paid_for_net_share_settlement_of_equity_awards": "d1#f-419", "repurchases_of_common_stock": "d1#f-422", "net_cash_from_financing_activities": "d1#f-431", "effect_of_exchange_rate_changes": "d1#f-434", "net_change_in_cash_cash_equivalents_and_restricted_cash": "d1#f-437", "cash_cash_equivalents_and_restricted_cash_end_of_period": "d1#f-443" }, "revenue_by_type": { "instruments_and_accessories": "d1#f-888", "systems": "d1#f-891", "services": "d1#f-894", "total_revenue": "d1#f-897" }, "revenue_by_geography": { "united_states": "d1#f-873", "outside_united_states": "d1#f-885" } }, { "period_end": "2024-12-31", "income_statement": { "product_revenue": "d1#f-134", "service_revenue": "d1#f-137", "total_revenue": "d1#f-140", "product_cost_of_revenue": "d1#f-143", "service_cost_of_revenue": "d1#f-146", "total_cost_of_revenue": "d1#f-149", "gross_profit": "d1#f-152", "selling_general_and_administrative": "d1#f-155", "research_and_development": "d1#f-158", "total_operating_expenses": "d1#f-161", "income_from_operations": "d1#f-164", "interest_and_other_income_net": "d1#f-167", "income_before_taxes": "d1#f-170", "income_tax_expense": "d1#f-173", "net_income": "d1#f-176", "net_income_attributable_to_noncontrolling_interest": "d1#f-305", "net_income_attributable_to_intuitive_surgical": "d1#f-182", "basic_eps": "d1#f-185", "diluted_eps": "d1#f-188", "basic_shares": "d1#f-191", "diluted_shares": "d1#f-194" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-57", "short_term_investments": "d1#f-59", "accounts_receivable_net": "d1#f-63", "inventory": "d1#f-65", "prepaids_and_other_current_assets": "d1#f-68", "total_current_assets": "d1#f-70", "property_plant_and_equipment_net": "d1#f-72", "long_term_investments": "d1#f-74", "deferred_tax_assets": "d1#f-76", "intangible_and_other_assets_net": "d1#f-78", "goodwill": "d1#f-80", "total_assets": "d1#f-82", "accounts_payable": "d1#f-84", "accrued_compensation_and_employee_benefits": "d1#f-86", "deferred_revenue": "d1#f-88", "other_accrued_liabilities": "d1#f-90", "total_current_liabilities": "d1#f-92", "other_long_term_liabilities": "d1#f-94", "total_liabilities": "d1#f-96", "additional_paid_in_capital": "d1#f-120", "retained_earnings": "d1#f-122", "accumulated_other_comprehensive_income_loss": "d1#f-124", "total_intuitive_surgical_stockholders_equity": "d1#f-126", "noncontrolling_interest_in_joint_venture": "d1#f-128", "total_stockholders_equity": "d1#f-130", "common_shares_outstanding": "d1#f-115", "cash_cash_equivalents_and_investments": "d1#f-675" }, "cash_flow": { "depreciation_and_loss_on_disposal_of_property_plant_and_equipment": "d1#f-357", "amortization_of_intangible_and_other_assets": "d1#f-360", "deferred_income_taxes": "d1#f-369", "share_based_compensation": "d1#f-372", "operating_cash_flow": "d1#f-396", "purchases_of_investments": "d1#f-399", "proceeds_from_sales_of_investments": "d1#f-402", "proceeds_from_maturities_of_investments": "d1#f-405", "capital_expenditures": "d1#f-408", "acquisitions_net_of_cash_intellectual_property_and_other_investing": "d1#f-411", "net_cash_from_investing_activities": "d1#f-414", "proceeds_from_employee_stock_plans": "d1#f-417", "taxes_paid_for_net_share_settlement_of_equity_awards": "d1#f-420", "net_cash_from_financing_activities": "d1#f-432", "effect_of_exchange_rate_changes": "d1#f-435", "net_change_in_cash_cash_equivalents_and_restricted_cash": "d1#f-438", "cash_cash_equivalents_and_restricted_cash_end_of_period": "d1#f-440" }, "revenue_by_type": { "instruments_and_accessories": "d1#f-889", "systems": "d1#f-892", "services": "d1#f-895", "total_revenue": "d1#f-898" }, "revenue_by_geography": { "united_states": "d1#f-874", "outside_united_states": "d1#f-886" } }, { "period_end": "2023-12-31", "income_statement": { "product_revenue": "d1#f-135", "service_revenue": "d1#f-138", "total_revenue": "d1#f-141", "product_cost_of_revenue": "d1#f-144", "service_cost_of_revenue": "d1#f-147", "total_cost_of_revenue": "d1#f-150", "gross_profit": "d1#f-153", "selling_general_and_administrative": "d1#f-156", "research_and_development": "d1#f-159", "total_operating_expenses": "d1#f-162", "income_from_operations": "d1#f-165", "interest_and_other_income_net": "d1#f-168", "income_before_taxes": "d1#f-171", "income_tax_expense": "d1#f-174", "net_income": "d1#f-177", "net_income_attributable_to_noncontrolling_interest": "d1#f-274", "net_income_attributable_to_intuitive_surgical": "d1#f-183", "basic_eps": "d1#f-186", "diluted_eps": "d1#f-189", "basic_shares": "d1#f-192", "diluted_shares": "d1#f-195" }, "cash_flow": { "depreciation_and_loss_on_disposal_of_property_plant_and_equipment": "d1#f-358", "amortization_of_intangible_and_other_assets": "d1#f-361", "deferred_income_taxes": "d1#f-370", "share_based_compensation": "d1#f-373", "operating_cash_flow": "d1#f-397", "purchases_of_investments": "d1#f-400", "proceeds_from_sales_of_investments": "d1#f-403", "proceeds_from_maturities_of_investments": "d1#f-406", "capital_expenditures": "d1#f-409", "acquisitions_net_of_cash_intellectual_property_and_other_investing": "d1#f-412", "net_cash_from_investing_activities": "d1#f-415", "proceeds_from_employee_stock_plans": "d1#f-418", "taxes_paid_for_net_share_settlement_of_equity_awards": "d1#f-421", "repurchases_of_common_stock": "d1#f-424", "net_cash_from_financing_activities": "d1#f-433", "effect_of_exchange_rate_changes": "d1#f-436", "net_change_in_cash_cash_equivalents_and_restricted_cash": "d1#f-439", "cash_cash_equivalents_and_restricted_cash_end_of_period": "d1#f-441" }, "revenue_by_type": { "instruments_and_accessories": "d1#f-890", "systems": "d1#f-893", "services": "d1#f-896", "total_revenue": "d1#f-899" }, "revenue_by_geography": { "united_states": "d1#f-875", "outside_united_states": "d1#f-887" } } ], "quarterly": [ { "period_end": "2026-09-30", "income_statement": { "product_revenue": "d2#f-104", "service_revenue": "d2#f-108", "total_revenue": "d2#f-112", "product_cost_of_revenue": "d2#f-116", "service_cost_of_revenue": "d2#f-120", "total_cost_of_revenue": "d2#f-124", "gross_profit": "d2#f-128", "selling_general_and_administrative": "d2#f-132", "antitrust_class_action_litigation_settlement": "d2#f-136", "research_and_development": "d2#f-140", "total_operating_expenses": "d2#f-144", "income_from_operations": "d2#f-148", "interest_and_other_income_net": "d2#f-152", "income_before_taxes": "d2#f-156", "income_tax_expense": "d2#f-160", "net_income": "d2#f-164", "net_income_attributable_to_noncontrolling_interest": "d2#f-809", "net_income_attributable_to_intuitive_surgical": "d2#f-172", "basic_eps": "d2#f-176", "diluted_eps": "d2#f-180", "basic_shares": "d2#f-184", "diluted_shares": "d2#f-188" }, "balance_sheet": { "cash_and_cash_equivalents": "d2#f-30", "short_term_investments": "d2#f-32", "accounts_receivable_net": "d2#f-34", "inventory": "d2#f-36", "prepaids_and_other_current_assets": "d2#f-38", "total_current_assets": "d2#f-40", "property_plant_and_equipment_net": "d2#f-42", "deferred_tax_assets": "d2#f-46", "intangible_and_other_assets_net": "d2#f-48", "goodwill": "d2#f-50", "total_assets": "d2#f-52", "accounts_payable": "d2#f-54", "accrued_compensation_and_employee_benefits": "d2#f-56", "deferred_revenue": "d2#f-58", "other_accrued_liabilities": "d2#f-60", "total_current_liabilities": "d2#f-62", "other_long_term_liabilities": "d2#f-64", "total_liabilities": "d2#f-66", "additional_paid_in_capital": "d2#f-90", "retained_earnings": "d2#f-92", "accumulated_other_comprehensive_income_loss": "d2#f-94", "total_intuitive_surgical_stockholders_equity": "d2#f-96", "noncontrolling_interest_in_joint_venture": "d2#f-98", "total_stockholders_equity": "d2#f-100", "common_shares_outstanding": "d2#f-84", "cash_cash_equivalents_and_investments": "d2#f-349" }, "revenue_by_type": { "instruments_and_accessories": "d2#f-588", "systems": "d2#f-592", "services": "d2#f-596", "total_revenue": "d2#f-600" }, "revenue_by_geography": { "united_states": "d2#f-568", "outside_united_states": "d2#f-584" }, "shareholder_returns": { "shares_repurchased": "d2#f-795", "aggregate_cost_of_shares_repurchased": "d2#f-800" } }, { "period_end": "2025-09-30", "income_statement": { "product_revenue": "d2#f-105", "service_revenue": "d2#f-109", "total_revenue": "d2#f-113", "product_cost_of_revenue": "d2#f-117", "service_cost_of_revenue": "d2#f-121", "total_cost_of_revenue": "d2#f-125", "gross_profit": "d2#f-129", "selling_general_and_administrative": "d2#f-133", "research_and_development": "d2#f-141", "total_operating_expenses": "d2#f-145", "income_from_operations": "d2#f-149", "interest_and_other_income_net": "d2#f-153", "income_before_taxes": "d2#f-157", "income_tax_expense": "d2#f-161", "net_income": "d2#f-165", "net_income_attributable_to_noncontrolling_interest": "d2#f-851", "net_income_attributable_to_intuitive_surgical": "d2#f-173", "basic_eps": "d2#f-177", "diluted_eps": "d2#f-181", "basic_shares": "d2#f-185", "diluted_shares": "d2#f-189" }, "revenue_by_type": { "instruments_and_accessories": "d2#f-589", "systems": "d2#f-593", "services": "d2#f-597", "total_revenue": "d2#f-601" }, "revenue_by_geography": { "united_states": "d2#f-569", "outside_united_states": "d2#f-585" }, "shareholder_returns": { "shares_repurchased": "d2#f-838", "aggregate_cost_of_shares_repurchased": "d2#f-842" }, "balance_sheet": { "total_intuitive_surgical_stockholders_equity": "d2#f-857", "noncontrolling_interest_in_joint_venture": "d2#f-858", "total_stockholders_equity": "d2#f-859", "common_shares_outstanding": "d2#f-852", "additional_paid_in_capital": "d2#f-854", "retained_earnings": "d2#f-855", "accumulated_other_comprehensive_income_loss": "d2#f-856" } } ] } }